Related Experiment Video
Updated: Jul 30, 2025
Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
Effectiveness of 0.01% atropine in anisomyopic children
Azfira Hussain1, Aparna Gopalakrishnan1, Saurav Chowdhury1
1Myopia Clinic, Unit of Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Insights
Low-dose atropine (0.01%) showed minimal effect in slowing myopia progression in children with anisomyopia. This study found no significant difference in ocular parameter changes between atropine and single vision spectacle wearers.
Area of Science:
- Ophthalmology
- Pediatric Ophthalmology
- Myopia Control
Background:
- Anisomyopia, a condition with unequal refractive error between eyes, presents unique challenges in myopia management.
- Low-dose atropine has emerged as a potential treatment for slowing myopia progression in children.
Purpose of the Study:
- To investigate the efficacy of 0.01% atropine in altering ocular parameters in children diagnosed with anisomyopia.
- To compare the progression of myopia and changes in ocular biometrics between anisomyopic children treated with 0.01% atropine and those using single vision spectacles.
Main Methods:
- A retrospective study analyzed data from 52 anisomyopic children (age 6-12 years) treated at a tertiary eye center.
- Participants were divided into two groups: those treated with 0.01% atropine and those prescribed single vision spectacles.
- Follow-up duration exceeded one year, with comprehensive ocular examinations recorded.
Main Results:
- No statistically significant difference was observed in the mean rate of change of spherical equivalent (SE) between the 0.01% atropine group and the single vision spectacle group for both more myopic and less myopic eyes.
- Ocular biometric parameters showed no significant differences between the two treatment groups.
- While a significant correlation between SE change and axial length was noted in the atropine group, the overall change was not significant compared to the control group.
Conclusions:
- The administration of 0.01% atropine demonstrated a minimal effect on reducing the rate of myopia progression in anisomyopic eyes.
- Current evidence suggests 0.01% atropine may not be an effective strategy for myopia control in anisomyopic children.
Purpose:
To investigate the change in ocular parameters of anisomyopic children treated with 0.01% atropine.
Methods:
This retrospective study analyzed the data of anisomyopic children who underwent comprehensive examination at a tertiary eye center in India. Anisomyopic subjects (difference of ≥1.00 D) of age 6-12 years who were treated with 0.01% atropine or prescribed regular single vision spectacle and had follow-ups of more than 1 year were included.
Results:
Data from 52 subjects were included. No difference was observed in the mean rate of change of spherical equivalent (SE) of more myopic eyes between 0.01% atropine (-0.56 D; 95% confidence interval [CI]: -0.82, -0.30) and single vision lens wearers (-0.59 D; 95% CI: -0.80, -0.37; P = 0.88). Similarly, insignificant change in the mean SE of less myopic eyes was noted between the groups (0.01% atropine group, -0.62 D; 95% CI: -0.88, -0.36 vs. single vision spectacle wearer group, -0.76 D; 95% CI: -1.00, -0.52; P = 0.43). None of the ocular biometric parameters showed any difference between the two groups. Though anisomyopic cohort treated with 0.01% atropine revealed a significant correlation between the rate of change of mean SE and axial length in both eyes (more myopic eyes, r = -0.58; P = 0.001 and less myopic eyes, r = -0.82; P < 0.001) compared to single vision spectacle wearer group, the change was not significant.
Conclusion:
Administration of 0.01% atropine had minimal effect on reducing the rate of myopia progression in anisomyopic eyes.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:28Angle Closure Glaucoma: Treatment